why choose us

First received: April 24, 2023

Clinical Trial: TEIPP Immunotherapy in Patients With NSCLC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non Small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: T-cell Epitopes Associated With Impaired Peptide Processing (TEIPP)- Targeting Immunotherapy in Patients With Relapsed Advanced Non Small Cell Lung Cancer (NSCLC)

Brief Summary: In this multicenter, open label non-randomized phase I/II dose escalation study with extension cohort HLA-A*0201-positive patients with non small cell lung cancer (NSCLC) can be included.The primary aim of this study is determine the safety, tolerability and immune modulating effects of the therapeutic LRPAP1 synthetic long peptide (LRPAP7-30V-SLP) vaccine (TEIPP24) at different doses.Secondary objectives are to assess the specificity and immune modulatory effects of the vaccine, to assess the antigen and…

Read more